Dependable, current, and complete, Robbins and Cotran Pathologic Basis of Disease, 9th Edition is the perennially best-selling text that you’ll use long after your medical student days are behind you. A world-class author team headed by Drs. Vinay Kumar, Abul Abbas, and Jon Aster, delivers the latest, most essential pathology knowledge in a readable, interesting […]
This issue of Hematology/Oncology Clinics will cover aggressive B-Cell Lymphoma and articles to be included are: State of the art therapy for advanced stage DLBCL; DLBCL: Should limited stage patients be treated differently; Role of PET in DLBCL; Management of relapsed DLBCL; The spectrum of double-hit lymphoma; Optimizing outcomes in primary mediastinal B cell lymphoma; […]
Diabetes, Hematology/Coagulation in Pregnancy, An Issue of Clinics in Laboratory Medicine, E-Book
This issue will assist the practicing pediatrician with providing evidence-based care to children with common, rare, inherited and acquired hematological disorders whom they regularly see in general pediatric practice. The information in this edition will support a general pediatrician’s understanding of recently developed diagnostic and therapeutic tools–for instance, techniques for the assessment of transfusional iron […]
This issue of Hematology/Oncology Clinics will feature articles such as: Anaplastic large cell lymphomaj; New agents; Transplant, Uncommon variants; ATLL, CD30+ LPD of skin; NK/T, MF/SS; and many more!
The unquestioned leader in dermatopathology resources, Weedon’s Skin Pathology returns with expanded and updated coverage in this specialized field of pathology. Offering an enhanced emphasis on differential diagnosis, new author Dr. James W. Patterson provides the most clinically relevant developments in molecular biology and techniques while maintaining Dr. Weedon’s consistent, uniform approach to the subject. […]
This issue of Hematology/Oncology Clinics will focus on lung cancer; specifically, Genomics in lung cancer; Neoadjuvant and adjuvant therapy for NSCLC; Treatment of locally advanced NSCLC; First line systemic therapy for NSCLC; Second line chemotherapy and beyond for NSCLC; Treatment of EGFR mutant tumors; Treatment of ALK positive tumors; New targets in NSCLC; Immunotherapy; Advances […]